A Dog's Second Chance, Designed by AI

When Australian tech entrepreneur Paul Conyngham learned in 2024 that his rescue dog Rosie had cancer, he refused to give up. After chemotherapy and surgery failed to stop the tumors, Conyngham — an electrical engineer with 17 years in data science and machine learning, but no background in biology — turned to artificial intelligence to do something that had never been done before: design a personalized cancer vaccine for a dog.

The result has stunned scientists and the broader tech world alike. Most of Rosie's tumors have shrunk dramatically, and she's back chasing rabbits at the dog park.

From the Chat Window to the Lab

Conyngham's journey began with a simple but audacious question to OpenAI's ChatGPT: how could he fight Rosie's cancer with immunotherapy? The AI directed him toward the University of New South Wales Ramaciotti Center for Genomics, where he paid for Rosie's full genomic sequencing.

"I went to ChatGPT and came up with a plan on how to do this," Conyngham told The Australian.

From there, he used AlphaFold, Google DeepMind's protein structure prediction tool, to identify mutated proteins in Rosie's tumor genome that could serve as targets for an immune response. He also used Grok, xAI's chatbot, during the research process. When the drug company that made a promising immunotherapy treatment wouldn't provide access to it, Conyngham turned to nanomedicine pioneer Pall Thordarson, director of UNSW's RNA Institute.

Thordarson and his team used Conyngham's AI-derived data to manufacture a bespoke mRNA vaccine — similar in approach to the COVID-19 mRNA vaccines — in under two months.

A Historic First

"This is the first time a personalized cancer vaccine has been designed for a dog," Thordarson said. "This is still at the frontier of where cancer immunotherapeutics are — and ultimately, we're going to use this for helping humans. What Rosie is teaching us is that personalized medicine can be very effective, and done in a time-sensitive manner, with mRNA technology."

Rosie received her first injection in December 2025, followed by a booster in February 2026. The results have been striking: the tumor on her leg shrank by approximately 75% within a month of the first injection, and her overall health has improved dramatically.

Implications Beyond One Dog

Thordarson posted about Rosie's progress in a thread on X, noting that the case demonstrates how technology can "democratize" the process of designing cancer vaccines. The implication is profound: if a non-biologist with AI tools and willing research partners can design a novel, effective cancer vaccine in months, what does that mean for the future of oncology?

Matt Shumer, co-founder and CEO of OthersideAI, flagged the story on X with a note that resonated widely:

"This is what I mean when I say the world is going to get very weird, very soon. Expect more stories like this, each sounding increasingly more insane."

Conyngham is clear-eyed about the limitations. Rosie is not cured — some tumors haven't responded to the vaccine, and the science is still early. But the quality of life improvement has been real.

"In December she had low energy because the tumors were creating a huge burden for her," Conyngham told The Australian. "Six weeks post-treatment, I was at the dog park when she spotted a rabbit and jumped the fence to chase it. I'm under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life."

What It Means for Human Medicine

Personalized cancer vaccines — where a patient's own tumor genome is sequenced and a custom immunotherapy designed to target their specific mutations — represent one of the most exciting frontiers in oncology. Companies like Moderna and BioNTech have been developing mRNA-based personalized cancer vaccines for humans, with promising early results in clinical trials for melanoma and other cancers.

What makes Rosie's story remarkable isn't just the outcome — it's the process. A determined non-expert, armed with AI tools that didn't exist five years ago, was able to compress what might have been years of research into months. As AI tools grow more capable and genomic sequencing becomes cheaper and faster, stories like Rosie's may stop being extraordinary and start being routine.

For now, though, one rescue dog in Australia is chasing rabbits — and the world is watching closely.